Search clinical trials for: Liposomal Doxorubicin

Total 2880 results

Zeneus Pharma

Unknown

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

Metastatic Breast Cancer

Italy
Philogen S.p.A.

Recruiting

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) (FIBROSARC US)

Leiomyosarcoma

United States
Merck Sharp & Dohme LLC
MDS Pharma Services

Completed

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Breast Neoplasm
Women and Infants Hospital of Rhode Island
Ortho Biotech, Inc.

Terminated

Doxil and Gemcitabine in Recurrent Ovarian Cancer

Ovarian Carcinoma

United States
Aptium Oncology Research Network
Ortho Biotech Products, L.P.

Unknown

Phase II Study in Patients With Operable Breast Cancer

Breast Cancer

United States
Guangxi Medical University

Withdrawn

Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma (LD-FOX4/HCC)

Hepatocellular Carcinoma
Johnson & Johnson Pharmaceutical Research & Development...
Centocor Ortho Biotech Services, L.L.C.

Completed

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Completed

Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISIONV)

Primary Liver Cancer

Austria, Switzerland, France, Germany
French Innovative Leukemia Organisation

Completed

Treatment of Disseminated High Grade Lymphoma

Lymphoma

France
University of Southern California

Terminated

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Primary Effusion Lymphomas

United States
Pharmatech Oncology

Unknown

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
Sequus Pharmaceuticals

Completed

Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma

HIV Infections | Sarcoma, Kaposi

United States
National Cancer Institute (NCI)

Active, not recruiting

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Kaposi Sarcoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
King Faisal Specialist Hospital & Research Center

Completed

Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Epithelial Ovarian Cancer
Celgene Corporation
Prologue Research International

Terminated

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
University of Texas Southwestern Medical Center
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Ovarian Cancer

United States
Jia Fan

Unknown

TACE as an Adjuvant Therapy After Hepatectomy for HCC

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.; CSPC ZhongQi Pharmaceutical Technology...

Not yet recruiting

Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy

Breast Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
Wyeth is now a wholly owned subsidiary of Pfizer; National Comprehensive Cancer...

Completed

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Sarcoma

United States
University of Iowa
Aventis Pharmaceuticals

Terminated

Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Roswell Park Cancer Institute
Ortho Biotech, Inc.

Completed

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
National Institute of Allergy and Infectious Diseases...
Amgen; Sequus Pharmaceuticals

Completed

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

HIV Infections | Sarcoma, Kaposi

United States
The University of Texas Health Science Center,...

Unknown

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer

United States
Hebei Medical University Fourth Hospital

Completed

Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer

Breast Cancer

China
Janssen Research & Development, LLC

Completed

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Neoplasms | Neoplasms, Breast | Neoplasms, Ovarian | Advanced or Refractory Solid Malignancies

United States, United Kingdom, Spain, Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ortho Biotech, Inc.

Completed

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Lymphoma

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University Hospital Birmingham

Unknown

Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

Liver Cancer

United Kingdom
North Eastern German Society of Gynaecological...

Completed

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University

Active, not recruiting

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Efficacy and Safety

China
Konkuk University Medical Center
National Cancer Center, Korea; Samsung Medical Center; Asan Medical Center; Seoul... and other collaborators

Completed

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Carcinoma

Korea, Republic of
Laurence J.C. van Warmerdam
Sanofi; Cephalon

Terminated

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer (MYOHERTAX)

Breast Cancer | Neoplasm Metastasis

Netherlands
Nexstar Pharmaceuticals

Completed

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

HIV Infections | Sarcoma, Kaposi

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Aravive, Inc.

Completed

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
National Cheng-Kung University Hospital

Completed

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer (Trientine)

Fallopian Tube Cancer | Peritoneal Carcinoma | Ovarian Neoplasms Malignant (Excl Germ Cell)
National Cancer Institute (NCI)

Completed

Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

Sarcoma, Kaposi

United States
Masonic Cancer Center, University of Minnesota
Celgene Corporation

Terminated

Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Washington University School of Medicine

Completed

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Resistant Solid Malignancies

United States
Sun Yat-sen University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Rhabdomyosarcoma, Child
Threshold Pharmaceuticals
Sarcoma Alliance for Research through Collaboration (SARC)

Completed

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, Canada, Spain, Germany, Belgium, Poland, Austria, Denmark, Hungary, Israel, Italy, Russian Federation
Broto, Javier Martín, M.D.

Unknown

Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum (GEIS-27)

Chondrosarcoma | Retroperitoneal Liposarcoma | Retroperitoneal Leiomyosarcoma

Spain
Hebei Medical University Fourth Hospital

Completed

A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer

Breast Cancer

China
Hebei Medical University Fourth Hospital

Unknown

Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer

Breast Cancer

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

Lymphoma | Large B-Cell | Diffuse Large B-Cell

Italy
Clemens Tempfer

Completed

A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis

Ovarian Cancer

Germany
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Liver Cancer

Canada

Search clinical trials for: Liposomal Doxorubicin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations